Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.

Holash J, Thurston G, Rudge JS, Yancopoulos GD, Adjei AA, Bergers G, Pytowski B, Pegram M, Gordon MS.

Cancer Metastasis Rev. 2006 Jun;25(2):243-52. Review. No abstract available.

PMID:
16770536
2.

Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.

Adjei AA.

Clin Lung Cancer. 2007 Feb;8 Suppl 2:S74-8. Review.

PMID:
17382028
3.

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.

Tortora G, Ciardiello F, Gasparini G.

Nat Clin Pract Oncol. 2008 Sep;5(9):521-30. doi: 10.1038/ncponc1161. Epub 2008 Jul 1. Review.

PMID:
18594498
4.

Targeting growth factors and angiogenesis; using small molecules in malignancy.

Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H.

Cancer Metastasis Rev. 2006 Jun;25(2):279-92. Review.

PMID:
16770540
5.

Angiogenesis. A boost for tumor starvation.

Marx J.

Science. 2003 Jul 25;301(5632):452-4. No abstract available. Erratum in: Science. 2003 Nov 21;302(5649):1333.

PMID:
12881543
6.

Anticancer therapy with angiogenesis inhibitors.

Ghilardi C, Bani MR, Giavazzi R.

Tumori. 2001 Nov-Dec;87(6):S14-6. Review. No abstract available.

PMID:
11989610
7.

ERBB receptors and cancer: the complexity of targeted inhibitors.

Hynes NE, Lane HA.

Nat Rev Cancer. 2005 May;5(5):341-54. Review. Erratum in: Nat Rev Cancer. 2005 Jul;5(7):580.

PMID:
15864276
8.

Target-based therapies in breast cancer: current status and future perspectives.

Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F.

Endocr Relat Cancer. 2009 Sep;16(3):675-702. doi: 10.1677/ERC-08-0208. Epub 2009 Jun 12. Review.

9.

From bench top to bedside.

Barinaga M.

Science. 1997 Nov 7;278(5340):1036-9. No abstract available.

PMID:
9381201
10.

Advances in the use of angiogenesis inhibitors in cancer.

Pinedo HM.

Cancer J. 2001 Nov-Dec;7 Suppl 3:S107-8. Review. No abstract available.

PMID:
11779080
11.

Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.

Tvorogov D, Anisimov A, Zheng W, Leppänen VM, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, Kalkkinen N, Lankinen H, Ojala PM, Alitalo K.

Cancer Cell. 2010 Dec 14;18(6):630-40. doi: 10.1016/j.ccr.2010.11.001. Epub 2010 Dec 2.

12.

Angiogenesis inhibitors in the treatment of lung cancer.

Sun S, Schiller JH.

Crit Rev Oncol Hematol. 2007 May;62(2):93-104. Epub 2007 Feb 15. Review.

PMID:
17306557
13.

Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.

Hutson TE, Sonpavde G, Galsky MD.

Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S31-9. Review.

PMID:
17239282
14.

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.

Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Mar;6(3):1123-32.

16.

Targeted therapies in lung cancer.

Besse B, Ropert S, Soria JC.

Ann Oncol. 2007 Jul;18 Suppl 9:ix135-42. Review. No abstract available.

17.

Targeted therapies: aiming for the bull's-eye.

Gaguski ME.

ONS Connect. 2007 Jul;22(7):8-12. No abstract available.

PMID:
17694778
18.

Novel pharmacological agents in clinical development for solid tumours.

Dy GK, Haluska P, Adjei AA.

Expert Opin Investig Drugs. 2001 Dec;10(12):2059-88. Review.

PMID:
11772306
19.

Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.

Newton HB.

Curr Opin Investig Drugs. 2007 Dec;8(12):1009-21. Review.

PMID:
18058572
20.

Growth factors as active participants in carcinogenesis: a perspective.

Halper J.

Vet Pathol. 2010 Jan;47(1):77-97. doi: 10.1177/0300985809352981. Review.

Items per page

Supplemental Content

Write to the Help Desk